Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | CTSH | P09668 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.52 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
| ▸ | GRPR | P30550 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484310 | 0.97 | CTSL (0.53) | GLP1RCTSLCTSSCTSKCTSH | |
| SCHEMBL29670477 | 0.95 | NPBWR1 (0.56) | GLP1RCTSLCTSSCTSKCTSH | |
| SCHEMBL30064553 | 0.95 | GLP1R (0.58) | GLP1RIL23RGRPR | |
| SCHEMBL30208638 | 0.95 | GLP1R (0.57) | GLP1RCXCR4IL23R | |
| SCHEMBL29489380 | 0.94 | CTSL (0.53) | GLP1RCTSLCTSSCTSKCTSH | |
| SCHEMBL29484311 | 0.94 | GLP1R (0.56) | GLP1RCTSLCTSSCTSKCTSH | |
| SCHEMBL30932143 | 0.93 | GLP1R (0.60) | GLP1RCXCR4 | |
| SCHEMBL30208639 | 0.93 | GLP1R (0.60) | GLP1RCXCR4IL23R | |
| SCHEMBL29613390 | 0.92 | IL23R (0.55) | GLP1RCTSLCTSSCTSKCTSH | |
| SCHEMBL29484321 | 0.92 | CTSL (0.52) | GLP1RCTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-12290566-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12251395-B2 | RNAS for complement inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2024-04-11 | — | — | US | disclosed |
| EP-4349363-A2 | DOSING REGIMENS | Apellis Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | SIXTH STREET LENDING PARTNERS | 2024-03-07 | — | — | US | disclosed |
| EP-3359555-B1 | DOSING REGIMENS | APELLIS PHARMACEUTICALS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2023-09-28 | — | — | US | disclosed |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | APELLIS PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | C3AR1, C5, CFH | GLP1R 898/4885CTSL 43/4885CTSS 178/4885 |
| US-12290566-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | GLP1R 392/4885CTSL 33/4885CTSS 106/4885 |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | C9, C3AR1, SERPINC1 | GLP1R 1092/4885CTSL 10/4885CTSS 101/4885 |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | C3AR1, C5AR1, SERPINC1 | GLP1R 177/4885CTSL 10/4885CTSS 56/4885 |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | GLP1R 392/4885CTSL 33/4885CTSS 106/4885 |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | GLP1R 279/4885CTSL 17/4885CTSS 50/4885 |
| US-12251395-B2 | RNAS for complement inhibition | SNRPE, RNASE1, SNRPF | GLP1R 4755/4885CTSL 1176/4885CTSS 1191/4885 |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SNRPE, RNASE1, SNRPF | GLP1R 4755/4885CTSL 1176/4885CTSS 1191/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | GLP1R 1096/4885CTSL 7/4885CTSS 58/4885 |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | C5, C3AR1, C1QBP | GLP1R 2417/4885CTSL 432/4885CTSS 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.